Jimenez offers bouquet to FDA's Hamburg

Novartis ($NVS) CEO Joe Jimenez (photo) is no stranger to the executive Q&A; he's been chatted up by almost every big media outlet there is. However, every once in a while, he drops a bit of new information into his spiel. With Smart Money, he offers mild kudos to Margaret Hamburg's FDA. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.